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Abstract Atherosclerosis is an immunoinflammatory pro-
cess that involves complex interactions between the vessel
wall and blood components and is thought to be initiated by
endothelial dysfunction [1–3]. Extracellular nucleotides that
are released from a variety of arterial and blood cells [4]
can bind to P2 receptors and modulate proliferation and
migration of smooth muscle cells (SMC), which is known
to be involved in intimal hyperplasia that accompanies
atherosclerosis and postangioplasty restenosis [5]. In
addition, P2 receptors mediate many other functions,
including platelet aggregation, leukocyte adherence, and
arterial vasomotoricity. A direct pathological role of P2
receptors is reinforced by recent evidence showing that up-
regulation and activation of P2Y2 receptors in rabbit
arteries mediates intimal hyperplasia [6]. In addition, up-
regulation of functional P2Y receptors also has been
demonstrated in the basilar artery of the rat double-
hemorrhage model [7] and in coronary arteries of diabetic
dyslipidemic pigs [8]. It has been proposed that up-
regulation of P2Y receptors may be a potential diagnostic
indicator for the early stages of atherosclerosis [9].
Therefore, particular effort must be made to understand
the consequences of nucleotide release from cells in the
cardiovascular system and the subsequent effects of P2
nucleotide receptor activation in blood vessels, which may






Atherosclerosis is a pathological phenomenon primarily
affecting the large conduit arteries, for example, the aorta
and coronary, carotid iliac, and femoral arteries. Develop-
ment of atherosclerotic lesions in arteries involves intimal
recruitment of smooth muscle cells (SMC) within the
blood-vessel wall and also infiltration of blood-derived
cells [1]. This process necessitates the proliferation and
migration of SMC from the underlying media and the
endothelial adhesion of leukocytes and their infiltration into
the subendothelium. A similar intimal accumulation of
SMC also takes place during the postangioplasty restenotic
process. Although the factors involved in intimal-cell
recruitment are not clearly identified, it is becoming evident
that endothelial dysfunction is a key factor in the
development of vascular disease. Experimental evidence
suggests that an intact endothelium plays a central role in
maintaining a low proliferative state of SMC under normal
conditions [10]. In arterial injury, endothelial cells, SMC,
and various blood cells can release chemotactic factors and
mitogens, including ATP and other nucleotides [4]. Acti-
vation of P2 nucleotide receptors has been shown to induce
not only the proliferation and migration of vascular SMC
but also apoptosis (programmed cell death), a process
involved in the evolution of atherosclerotic plaque [11]. In
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vasoconstriction of arteries that may be involved in the
vascular remodeling accompanying atherosclerosis and
postangioplasty restenosis [5]. A better understanding of
the causative agents and mechanisms of proliferation and
migration of vascular SMC as well as recruitment of
blood-derived cells by the endothelium could lead to
prevention, attenuation, or even reversal of intimal thick-
ening, which may dramatically reduce morbidity and
mortality from vascular diseases such as atherosclerosis
and restenosis after angioplasty. In this respect, a better
understanding of the physiological role of P2 receptors in
both normal and pathological blood vessels could poten-
tially lead to a breakthrough in the fight against vascular
disease.
P2 receptors in the cardiovascular system
Extracellular nucleotides bind to cell-surface receptors
known as P2 receptors, which are present in many tissues.
To date, these receptors have been classified into two main
families: the P2X receptors that are ligand-gated ion
channels comprised of homo- or hetero-oligomers [12],
and P2Y receptors that are seven-membrane-spanning
receptors coupled via G proteins (Gq/11 or Gi/o) to phos-
pholipase C (PLC) and/or adenylate cyclase [12–14]. In
turn, PLC activation generates inositol 1,4,5-triphosphate
(IP3), a mediator of Ca
2+ release from intracellular stores,
and diacylglycerol, an activator of protein kinase C (PKC)
whereas adenylate cyclase generates cyclic AMP, an
activator of protein kinase A (PKA). The cloning of seven
P2X (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, P2X7) and
eight P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
P2Y14) receptor subtypes has made it possible to use
molecular and pharmacological approaches to study the
distribution and functional properties of specific P2
receptor subtypes at the tissue and cellular level.
P2 receptors in vascular cells
The normal arterial wall consists of three layers: intima,
media, and adventitia. The single layer of endothelial cells
facing the vessel lumen is a very important component of
the vascular wall in terms of releasing both vasodilators
such as nitric oxide (NO) and prostacyclin (PGI2), and
vasoconstrictors such as thromboxane A2 and endothelin.
The principal P2Y receptor subtypes that have been
functionally characterized in endothelial cells are P2Y1
and P2Y2, but mRNAs for P2Y4 and P2Y6 receptors have
also been detected [4]. Endothelium-dependent vasorelax-
ation has been attributed to the release of NO and PGI2
after binding of nucleotides to P2Y1 and P2Y2 receptors in
endothelial cells [15] whereas vasoconstrictor effects in
SMC result from the action of nucleotides on P2Y2 and
P2X receptors [16, 17]. In most blood vessels, P2Y1 re-
ceptors for ADP are present on the endothelium and
regulate vasodilatation by Ca
2+-dependent (PLC-mediated)
activation of NO synthase (NOS) and generation of
endothelial-dependent relaxing factor (EDRF) [4]. Endo-
thelial prostacyclin production is also stimulated by
P2Y1 and P2Y2 receptors, but this seems to play a minimal
role in vasodilatation, at least under physiological con-
ditions [18]. Recent studies have indicated that in the aorta
of P2Y2-null mice, the endothelium-dependent relaxation
by ATP and ATPγS was inhibited, demonstrating the role
of the P2Y2 receptors, but that a relaxation by UTP and
UDP was maintained, suggesting the additional involve-
ment of P2Y6 receptors [19]. The majority of cells in intact
blood vessels are SMC, which occupy most of the media
and are involved in vessel vasoconstriction and vaso-
relaxation. P2Y2Rs in SMC mediate the induction of
immediate-early and delayed-early cell-cycle-dependent
genes, consistent with a role for P2Y2Rs in vascular
proliferation of SMC [20, 21]. A recent study demonstrated
that P2Y2 is the predominant functional receptor that
responds to ATP and UTP in rat aortic SMC [22]. In
human cerebral arteries, P2Y6 seems to be the predominant
subtype and induces vasoconstriction when activated by
UDP/UTP [23, 24]. This is consistent with findings from
rat pulmonary and mesenteric arteries [25, 26]. In addition,
a recent study on P2X1 knock-out mice further supports the
prominent contractile effect of the P2Y6 subtype in
mesenteric arterial trees [27]. Taken together, it seems that
the principal receptor mediating UTP/UDP-induced con-
tractile responses in blood vessels might be the P2Y6
subtype. Other studies have reported the presence of both
P2Y4 and P2Y6 receptors in rat aortic SMC [21, 28, 29].
P2Y1 receptors are expressed in SMC of a number of blood
vessel types and, like their endothelial cell counterparts,
mediate vasodilatation most likely through the activation of
K
+ channels [18]. The presence of several P2X receptor
subtypes also has been reported in human saphenous vein
SMC, including P2X1, P2X2, P2X4, and P2X7 receptors
[30]. The outermost layer of the blood vessel consists of
connective tissue and fibroblasts, which have not been
appreciated in the regulation of vascular tone. A recent
study showed that fibroblasts can migrate into the
neointima, suggesting their possible involvement in the
development of vascular diseases such as atherosclerosis
and restenosis after angioplasty [31]. Since human and rat
fibroblasts are known to express P2Y1, P2Y2, P2Y4, P2Y6,
P2X3,P 2 X 4, and P2X7 receptors [32], further investigation
is needed to establish the role of fibroblast P2 receptors
in either physiological or pathophysiological conditions.
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G-protein-coupled P2Y receptors the activation of which
leads to intracellular calcium mobilization have been
observed in neutrophils [4, 33, 34], and turkey erythrocytes
express both P2Y1 and P2X7 receptors [35, 36]. ATP and
UTP act as secretagogues by binding to P2Y2Rs to enhance
exocytosis of primary granules in neutrophils [37]. In
macrophages, ATP activates a P2X7 receptor that differs
from other ligand-gated ion-channel P2X receptors by its
ability to generate plasma membrane pores when activated
[38]. Human T lymphocytes also have been shown to
express P2X7 receptors [39]. Human monocytes and
macrophages coexpress P2X1, P2X4, and P2X7 receptors
whereas granulocytes only express P2X7 receptors [40].
P2Y1, P2Y2, and P2Y6 receptors also are expressed in
monocytes, B lymphocytes, and polymorphonuclear gran-
ulocytes [41]. Human platelets express P2Y1, P2Y12, and
P2X1 receptors [42–44]. Thus, the diversity of P2-receptor
expression in blood cells, as well as endothelial cells, SMC
and fibroblasts, suggests that this receptor superfamily
plays a significant role in the regulation of cardiovascular
functions.
P2 receptors regulate nucleotide-induced vascular
smooth muscle cell proliferation
Proliferation of SMC is a hallmark of vascular diseases
such as atherosclerosis and restenosis following angioplas-
ty. ATP and other nucleotides are released by aggregating
platelets and damaged vascular cells, such as endothelial
cells and SMC in pathological or stress conditions [45].
Extracellular nucleotides can act via P2X and P2Y
receptors to induce acute responses such as regulation of
vascular tone [46]. However, it is generally believed that
the ionotropic P2X receptors do not mediate the chronic
responses of nucleotides, such as cell proliferation. The
mitogenic effect of extracellular nucleotides on vascular
SMC (VSMC) has been known for years [47]. However, a
potent antiproliferative effect of UTP on VSMC also has
been reported in human arterial and venous SMC [48]. In
either case, the P2 receptor subtype(s) responsible for these
effects on the proliferation of VSMC has not been
determined. Earlier studies have shown that ATP or UTP
increases DNA and protein synthesis in subcultured rat
aortic VSMC [49, 50]. In the same cell-culture model,
however, Malam-Souley et al. [51] were unable to detect
increases in DNA synthesis after ATP/UTP stimulation
although ATP or UTP up-regulated the expression of
mRNA to several cell-cycle, progression-related genes.
Because P2X receptor agonists were essentially inactive,
it was concluded that a P2U-like receptor (now termed
P2Y2) was responsible for the mitogenic effects of ATP/
UTP. However, the role of a P2Y4 receptor cannot be
excluded because the nucleotide agonist profile between rat
P2Y2 and P2Y4 receptors is essentially indistinguishable
[52]. Indeed, Harper et al. [53] suggested that the P2Y4
receptor mediated ATP/UTP-induced proliferation of rat
aortic VSMC. Recent studies indicated that ATP, UTP, or
ITP, three agonists of the cloned porcine P2Y2 receptor,
increased DNA and protein synthesis and cell number in
coronary artery SMC [54]. Indeed, treatment of pig
coronary artery SMC with UTP, ATP, or ITP caused a
concentration-dependent increase in DNA and protein
synthesis and cell number whereas UDP only caused a
small increase in protein synthesis. Intriguingly, ATP was
much more potent and efficacious than UTP, ITP, and UDP
in increasing DNA synthesis and expression of PCNA, a
protein marker of cell proliferation, suggesting that another
receptor may contribute to the proliferative response [54].
In vivo experiments have shown that intimal thickening of
collared rabbit carotid arteries was greatly enhanced by in
situ UTP application and was closely associated with
osteopontin expression in medial SMC [6]. Osteopontin is
chemotactic for SMC and is associated with arterial SMC
proliferation [55]. Moreover, both UTP and ATP increased
osteopontin expression in cultured SMC whereas ADP,
UDP, and 2-MeSATP were ineffective, which suggests a
role for the P2Y2R in which ATP and UTP are equipotent.
Direct evidence for involvement of the P2Y2Rw a s
provided by inhibition of UTP-induced osteopontin expres-
sion in cultured SMC by P2Y2 antisense oligonucleotides
[6]. P2Y6 receptors also have been shown to mediate
proliferation of SMC in rat aorta [56].
Role of P2 receptors in the migration of vascular SMC
Recent studies indicate that the extracellular nucleotides
ATP, ADP, UTP, and UDP serve as directional cues for
migration of rat aortic SMC [57]. At identical concen-
trations, the most powerful migratory response induced by
these nucleotides was elicited by UTP. Nucleotide-induced
migration of SMC is the consequence of both chemotaxis
and chemokinesis and may result either from activation of
one particular P2 nucleotide receptor subtype or of several
P2 receptor subtypes. The ability of UTP at submicromolar
levels to stimulate migration of SMC supports the hypoth-
esis that this response could have physiological consequen-
ces and is essentially mediated by P2Y2 receptor activation
without excluding participation of other P2Y receptor
subtypes. The difference in the capacity of UTP and ATP
to elicit migration of SMC could be due to inhibition of
nucleotide-induced cell migration by adenosine generated
from ATP catabolism by cell-surface ectonucleotidases.
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migration of SMC when ATP was prevented from degra-
dation by addition of the ectonucleotidase inhibitor α,β-
methylene-ATP [57]. Several P2Y receptor subtypes could
be involved in nucleotide-induced migration of SMC. It has
been shown in rat aortic SMC that the P2Y2 receptor is the
predominant P2Y receptor subtype [28, 58] whereas lower
levels of P2Y4 and P2Y1 receptor mRNA were detected
[58]. The very low level of P2Y1 receptor mRNA
expression was consistent with the absence of ADP-
induced migration of cultured rat aortic SMC, demonstrat-
ing that P2Y1 is not involved in this process [58]. In
addition, the same study showed that a commercially
available solution of hexokinase-treated UDP (UTP-free)
induced cell migration equally as well as untreated UDP,
thereby demonstrating that UDP is chemotactic for aortic
SMC by activation of the P2Y6 receptor. Conversely,
migration of rat aortic SMC induced by UTP occurred
even when UTP degradation by nucleoside diphosphate
kinase was inhibited, demonstrating the involvement of
P2Y2 and/or P2Y4 receptor(s) [58].
The increased migration of SMC in response to extracel-
lular nucleotides could be related to increases in extracellular
matrix (ECM) protein expression. Indeed, previous studies
have shown that UTP induces osteopontin expression in rat
and rabbit aortic SMC [6, 51]. Increased expression of
osteopontin, an RGD-containing ECM protein, is associat-
ed with the activation of rat arterial SMC in vitro and in
vivo [57]. The increase in osteopontin expression plays a
key role in UTP-induced migration of rat aortic SMC since
a monoclonal antibody against osteopontin fully abolished
UTP-induced migration [57] whereas an antibody against
vitronectin, another ECM protein also involved in migra-
tion of human SMC [59], had no effect on the migration of
rat aortic SMC [57]. UTP induces increases in osteopontin
mRNA expression by increasing both osteopontin mRNA
stabilization and osteopontin promoter activity [60]. Recent
studies have shown that activation of an AP-1 binding site
located 76 bp upstream of the transcription start in the rat
osteopontin promoter is involved in UTP-induced osteo-
pontin expression. Using a luciferase promoter deletion
assay, Renault et al. [61] identified a new region of the rat
osteopontin promoter (−1837 to −1757) that is responsive
to UTP. This region contains an NFB site located at −1800
and an Ebox located at −1768. Supershift electrophoretic
mobility shift and chromatin immunoprecipitation assays
identified NFB and USF-1/USF-2 as DNA-binding proteins
induced by UTP. Using dominant negative mutants of IB
kinase and USF transcription factors, it was confirmed that
NFB and USF-1/USF-2 are involved in the UTP-induced
expression of osteopontin.
This ability of nucleotides to act as chemoattractants for
rat arterial SMC in a concentration range potentially found
in pathological vessels [62] and the findings of previous
studies demonstrating the mitogenic activity of extracellular
nucleotides for these cells suggest that nucleotides released
from mechanically stretched vascular or damaged cells
during the angioplasty process may participate in arterial-
wall remodeling.
Role of P2 receptors in nucleotide-induced
vascular inflammation
In addition to their mitogenic effects, extracellular nucleo-
tides may also cause cell recruitment by inducing lympho-
cyte and macrophage adhesion to human pulmonary artery
endothelial cells, as demonstrated in vitro [63]. Nucleotides
can also modulate rat aortic SMC adhesion and migration
by increasing the expression of osteopontin [51, 57], a
protein involved in both processes. Moreover, extracellular
nucleotides may play a role in intra-arterial attraction of
monocytes by inducing an increased expression of mono-
cyte-chemoattractant protein-1 by arterial SMC [21].
Stimulation of P2 receptors is coupled to the release of
the proinflammatory cytokines IL-1β, IL-1α, IL-8, and
TNF-α [4] that are of obvious relevance to inflammation in
atherosclerosis. Activation of P2X7 receptors on mono-
cytes/macrophages enhances release of proinflammatory
cytokines that modulate NO production and expression of
inducible NO synthase (iNOS) [64], mediators of immune
cell activation that is an early step in atherosclerotic lesion
development.
Monocyte recruitment into the vessel wall is a complex
process that includes cell rolling, firm attachment, and
directed migration. It is now becoming evident that ad-
hesion molecules such as VCAM-1 play an important role
in leukocyte adherence to vascular endothelial cells [65,
66]. VCAM-1 expression is induced or up-regulated by
proinflammatory cytokines such as TNF-α and IL-1β in
cellular components of the arterial wall, including endothe-
lial cells, SMC, and fibroblasts [67–69]. ATP and UTP have
been shown to induce cell–cell adhesion in a human
monocyte/macrophage lineage and neutrophil adherence to
human endothelial cell monolayers [63, 70].
Recent studies have shown that local UTP delivery via
an osmotic pump to collared rabbit carotid arteries induced
intimal accumulation of macrophages, similar to oxidized
low-density lipoprotein (LDL), a response that was medi-
ated by activation of P2Y2 receptors [6]. Leukocyte
migration depends on the activities of adhesion proteins
(e.g., selectins and integrins) on leukocytes and vascular
endothelial cells. We demonstrated that activation of
P2Y2 receptors in endothelial cells causes expression of
VCAM-1 that mediates adherence of monocytes to vascular
endothelium [71], leading to their penetration into the
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with atherosclerosis.
Recent studies revealed that a Src homology-3 (SH3)-
binding domain in the C-terminal tail of the P2Y2 receptor
promotes nucleotide-induced association of Src with the
P2Y2 receptor, leading to transactivation of growth factor
receptors, such as the EGF and VEGF receptors, and nu-
cleotide-induced up-regulation of VCAM-1 [72, 73]. Since
leukocyte infiltration and migration are key processes
involved in atherosclerosis, these findings suggest that
P2Y2 receptors represent a novel target for reducing arterial
inflammation associated with cardiovascular disease.
P2 receptors in vascular apoptosis
Apoptosis has been reported to occur in various vascular
diseases, such as atherosclerosis, restenosis, and hyperten-
sion [74, 75]. The major cell types undergoing apoptosis in
human atherosclerotic lesions are arterial SMC [11, 76–78]
and macrophages [79]. In restenosis following balloon
angioplasty, there is a peak in the proliferation and
apoptosis of rat vascular SMC 14 days postangioplasty
[76]. Furthermore, apoptosis of arterial SMC has been
described in animal models of intimal thickenings [80] and
probably takes part in the normal process involved in the
control of hyperplasia. In contrast, apoptosis of SMC in
advanced human atherosclerotic plaques may destabilize
the fibrous lesion to promote plaque rupture and its clinical
consequences.
As a mediator of cell-to-cell communication, ATP can
trigger a variety of biological responses after being rapidly
released in large amounts from various sources, including
activated platelets, endothelial cells, nerve terminals,
antigen-stimulated T cells, and other cell types following
hypoxia, stress, and tissue damage. For example, in human
umbilical cord vein endothelial cells (HUVEC), substantial
release of ATP (and UTP) is induced by shear stress [81],
which may lead to alterations in the balance between
proliferation and apoptosis regulated by P1 adenosine and
P2 (particularly P2X7) nucleotide receptors [82]. P2X7 and
P1 receptors have been previously linked to apoptosis in
other cell types, including immune cells, astrocytes, and
thymocytes [83–85]. The P2X7R also has been shown to
mediate ATP-induced cell death in human embryonic
kidney cells [86], human cervical epithelial cells [87], and
primary rat cortical neurons [88]. In human arterial SMC,
adenosine-induced apoptosis is essentially mediated via the
A2b-adenosine receptor subtype and involves a cAMP-
dependent pathway [89].
As an important constituent of atherosclerotic plaques,
fibroblasts share several features with SMC. In human
fibroblasts, P2X7 was identified as the main nucleotide
receptor involved in the high glucose concentration-
dependent responses modulated by ATP, including
morphological changes, enhanced apoptosis, caspase-3
activation, and IL-6 release [90]. In the immune system,
ATP also plays important roles through nucleotide receptors
in leukocyte functions. P2X7-receptor-mediated apoptosis
has been demonstrated in various types of leukocytes,
including a lymphocytic cell line, murine thymocytes, mu-
rine peritoneal macrophages, human macrophages, mesan-
gial cells, dendritic cells, and microglial cells [83, 91–96].
Extracellular ATP acting via the P2X7 receptor activates the
transcription factor NF-κB by selectively targeting NF-κB
p65 (Rel A) in the N9 mouse microglial cell line [97]. It
also has been reported that the P2X7 receptor modulates
macrophage production of TNF-α, IL-1β and NO follow-
ing LPS exposure [98], consistent with a role for the P2X7
receptor in inflammation. In HUVEC, TNF-α markedly
increases apoptotic cell death via the activation of caspase-3
[74]. Recent reports indicate that ATP/ADP activate NF-κB
and induce apoptosis, probably through P2X7 receptors in
porcine aortic endothelial cells [99]. These studies have
provided compelling evidence suggesting a role for P2- and
P1-receptor-mediated apoptosis in vascular diseases; how-
ever, further studies are needed to determine the precise
pathways involved and to accumulate direct evidence that
these pathways contribute significantly to the development
of atherosclerosis, hypertension, and restenosis.
Modulation of P2 receptors in vascular injury
Experimental arterial intimal hyperplasia can be induced by
balloon angioplasty or by perivascular placement of a
silicone collar around an artery. An influx of leukocytes
precedes migration and proliferation of vascular SMC into
the intima in both these models [100]. In normal adult rat
aorta, P2Y2 mRNA was found in endothelial cell lining
while a sustained expression of P2Y2 mRNA was detected
in a few medial SMC [20]. In contrast, P2Y2 mRNA was
detected in all medial SMC of rat fetal aortas and in most
aortic SMC of intimal lesions after balloon angioplasty,
with an overexpression in cells lining the lumen both 1 and
3 weeks after injury.
In the collar model, neointimal formation appears to be
triphasic [100]. The first phase is characterized by vascular
infiltration of leukocytes beginning 2 h after collar
placement around a rabbit carotid artery. The second phase
begins within 12 h of collar placement and is characterized
by medial replication of SMC. The third phase is
characterized by the appearance, beginning at day 3 after
collar placement, of subendothelial SMC. In situ hybrid-
ization with sham-operated rabbit carotid arteries indicated
that P2Y2 mRNA expression was localized to CD31-
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High levels of P2Y2 mRNA were detected in medial SMC
3 days after collar placement, before appearance of neo-
intima. At day 14, all intimal and medial SMC were P2Y2
positive. Fura-2 digital imaging of single SMC, used to
measure changes in myoplasmic calcium concentration in
response to P2Y receptor agonists, confirmed an increase in
P2Y2 receptor activity. However, the same study showed
that P2Y4 mRNA was equivalently expressed in sham-
operated and collared arteries or cultured rabbit carotid
SMC whereas P2Y6 mRNA was not detected in carotid
arteries or cultured SMC. In a more recent study, it was
shown that P2Y2 receptor up-regulation occurs in stented
porcine coronary artery, a clinically relevant model of
arterial injury [54]. P2Y2 receptor mRNA levels were
significantly increased in coronary SMC dispersed from
stented segments of coronary arteries 3 weeks after stent
angioplasty compared with SMC from unstented segments.
There was no significant difference observed in levels of
P2Y6 mRNA in the stented and unstented artery segments
whereas P2Y4 receptor mRNA was undetectable.
Up-regulation of functional P2Y receptors also occurs in
the basilar artery of the rat double-hemorrhage model [7], in
the coronary artery of diabetic dyslipidemic pigs [8], and
in human atherosclerotic lesions (Seye and Desgranges,
unpublished data). It has been proposed that up-regulation
of P2Y receptors could be a potential diagnostic indicator
for the early stages of atherosclerosis [9]. Interestingly, a
more recent study showed that high shear stress associated
with vascular diseases can selectively up-regulate P2Y2 and
P2Y6 receptors in perfused arterial SMC [101]. P2X1 and
P2X4 receptors have been shown to be up-regulated in
rabbit intimal thickenings [102]. Taken together, these
findings strongly suggest that at least some P2 receptor
subtypes (most notably P2Y2) are implicated in the
development of vascular disease.
Pathophysiological significance of P2 receptor
modulation in vascular injury
Migrating and proliferating SMC in the arterial media,
together with infiltrating macrophages and T lymphocytes,
are the main cell types that comprise atherosclerotic and
restenotic lesions [1]. In the early stages of intimal
hyperplasia, SMC are modified from a differentiated,
contractile phenotype to an immature, synthetic phenotype,
and this enables them to migrate into the intima, proliferate,
and secrete extracellular matrix components. In many
respects, this shift in phenotype is a reversal of the normal
differentiation pattern of vascular SMC during fetal and
early postnatal life [103, 104]. However, there is still a lack
of knowledge concerning the phenotypic regulation of
SMC during vasculogenesis and vascular disease. A high
level of P2 receptor expression could be related to the
altered phenotype of SMC in intimal thickenings. Partially
dedifferentiated SMC are found in rat arterial intimal
lesions after balloon angioplasty [105, 106], and their
phenotype has been compared with that of newborn rat
aortic SMC [107]. Interestingly, it has been reported that
medial SMC of rat embryonic aorta also exhibit high P2Y2
expression similar to intimal thickenings [20]. Others
studies have shown that P2Y1 and P2Y2 receptor transcripts
are strongly up-regulated with phenotypic changes in rat
SMC whereas P2X1 mRNA is completely down-regulated
and P2Y4 and P2Y6 mRNA levels are unchanged [28, 58].
Taken together, these and other results suggest that P2Y2
receptor expression is up-regulated in the entire cell
population of intimal thickenings and is closely associated
with a poorly differentiated phenotype of SMC. The
dramatic increase in P2Y2 mRNA expression observed in
balloon angioplasty-induced intimal lesions would suggest
increased activity of extracellular nucleotides with conse-
quent enhancement of cell proliferation and vasoreactivity.
Indeed, extracellular nucleotides, particularly ATP and
UTP, have been shown to induce cell-cycle progression
and proliferation of cultured arterial SMC [21, 49, 50, 51]
and vasoconstriction in the absence of endothelial cells [17,
108, 109]. Since both neointimal hyperplasia and vasocon-
strictive remodeling have been found to be involved in
postangioplasty restenosis [1, 5, 107, 110], these findings
suggest that extracellular nucleotides may play a significant
role in this process, at least as long as functional endothelial
cells, which regulate intimal thickening [111, 112] and
nucleotide-induced vasorelaxation [113, 114], are not
regenerated.
Increased P2Y2 receptor expression in the neointima
may by itself be sufficient to enhance local effects of
extracellular nucleotides on proliferation of SMC. Although
expression of other P2 receptors has been described in
arterial SMC [21, 29, 115], the P2Y2 receptor seems to be
more specifically involved in the response of SMC to ATP
and UTP [116], particularly in potentiation of proliferation
[21, 50]. Effects of extracellular nucleotides are not only
dependent on the nature and number of P2 receptors present
on target cells but also on local concentrations of nucleotide
agonists. Although in vivo concentrations of extracellular
nucleotides are difficult to measure, various in vitro
experiments suggest that extracellular nucleotides are
released from blood and vascular cells exposed to various
physicochemical conditions, e.g., stress, hypoxia, and other
factors [117–119] associated with the angioplasty process.
P2Y2 receptors in SMC are involved in nucleotide-
induced constriction of normal arteries [17, 108, 109].
Long-lasting alterations in vasomotricity after endothelial-
cell denudation, resulting in increased sensitivity to
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strated [113, 114]. It appears that, like other receptors for
vasoconstrictive factors such as angiotensin II [120],
endothelin [121], and PDGF [122], which are overex-
pressed in neointima, P2Y2 receptors may play an impor-
tant role in controlling vasoactive properties of pathological
arteries, particularly in chronic constriction at the lesion site
that is postulated to be one of the processes leading to
postangioplasty restenosis [5, 110].
Conclusion
P2 receptor subtypes, including P2Y2, P2X1 and P2X4,
appear to play a role in responses to endothelial injury that
are thought to be key events in the initiation of atheroscle-
rosis and restenosis after angioplasty. P2Y2R up-regulation
and activation in endothelial cells and SMC promote
leukocyte transmigration and intimal thickening in arteries
of animal models of vascular injury, suggesting a possible
regulatory role for this receptor in mechanisms leading to
neointimal hyperplasia after angioplasty. Although there are
no selective P2Y2 receptor antagonists yet available, recent
progress in small interfering RNA (siRNA) technology has
made it possible to design small RNA interference
molecules that can selectively inhibit P2 receptor subtype
expression. Such molecules can be efficiently delivered into
the vessel wall using adenoviral vectors. In addition, P2
receptor transgenic mice (i.e., mice in which the relevant
receptor subtype has been deleted or overexpressed) will be
valuable tools to substantiate the role that nucleotides and
P2 receptors play in the etiology of cardiovascular disease.
Further delineation of signaling pathways involved in these
P2 receptor-mediated processes may help limit or prevent
vascular diseases such as atherosclerosis and restenosis
after angioplasty.
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